– Biologics License Application (BLA) for IV efgartigimod accepted for review by U.S. Food and Drug Administration (FDA) for generalized myasthenia gravis (gMG) – Pre-approval
Tag: argenx
argenx to Report Complete 12 months 2020 Economic Effects and Fourth Quarter Business enterprise Update on March 4, 2021
TipRanks 3 Stocks Goldman Sachs Suggests Are All set to Rip Greater Is the bull market place about to choose a lengthy breather? Not in